Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy CRISPR Therapeutics stock | $90.16

Own CRISPR Therapeutics stock in just a few minutes.

Fact checked

CRISPR Therapeutics AG is a biotechnology business based in the US. CRISPR Therapeutics shares (CRSP) are listed on the NASDAQ and all prices are listed in US Dollars. CRISPR Therapeutics employs 304 staff and has a trailing 12-month revenue of around USD$77.4 million.

How to buy shares in CRISPR Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for CRISPR Therapeutics. Find the stock by name or ticker symbol: CRSP. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until CRISPR Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$90.16, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of CRISPR Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of CRISPR Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

CRISPR Therapeutics share price

Use our graph to track the performance of CRSP stocks over time.

CRISPR Therapeutics shares at a glance

Information last updated 2021-01-14.
Latest market closeUSD$90.16
52-week rangeUSD$32.3 - USD$210.39
50-day moving average USD$156.4042
200-day moving average USD$107.4938
Wall St. target priceUSD$146.56
PE ratio 124.3433
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.316

Buy CRISPR Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy CRISPR Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

CRISPR Therapeutics price performance over time

Historical closes compared with the close of $90.16 from 2020-10-22

1 week (2021-01-12) -52.63%
1 month (2020-12-18) -39.33%
3 months (2020-10-19) -16.30%
6 months (2020-07-17) -2.37%
1 year (2020-01-17) 54.57%
2 years (2019-01-18) 142.82%
3 years (2018-01-19) 203.26%
5 years (2016-01-15) N/A

Is CRISPR Therapeutics under- or over-valued?

Valuing CRISPR Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CRISPR Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

CRISPR Therapeutics's P/E ratio

CRISPR Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 124x. In other words, CRISPR Therapeutics shares trade at around 124x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

CRISPR Therapeutics's EBITDA

CRISPR Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$2.9 million.

The EBITDA is a measure of a CRISPR Therapeutics's overall financial performance and is widely used to measure a its profitability.

CRISPR Therapeutics financials

Revenue TTM USD$77.4 million
Gross profit TTM USD$110.2 million
Return on assets TTM -13.36%
Return on equity TTM -21.84%
Profit margin -273.1%
Book value $19.026
Market capitalisation USD$14.1 billion

TTM: trailing 12 months

Shorting CRISPR Therapeutics shares

There are currently 3.6 million CRISPR Therapeutics shares held short by investors – that's known as CRISPR Therapeutics's "short interest". This figure is 16.2% down from 4.3 million last month.

There are a few different ways that this level of interest in shorting CRISPR Therapeutics shares can be evaluated.

CRISPR Therapeutics's "short interest ratio" (SIR)

CRISPR Therapeutics's "short interest ratio" (SIR) is the quantity of CRISPR Therapeutics shares currently shorted divided by the average quantity of CRISPR Therapeutics shares traded daily (recently around 2.0 million). CRISPR Therapeutics's SIR currently stands at 1.78. In other words for every 100,000 CRISPR Therapeutics shares traded daily on the market, roughly 1780 shares are currently held short.

However CRISPR Therapeutics's short interest can also be evaluated against the total number of CRISPR Therapeutics shares, or, against the total number of tradable CRISPR Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CRISPR Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 CRISPR Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0618% of the tradable shares (for every 100,000 tradable CRISPR Therapeutics shares, roughly 62 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against CRISPR Therapeutics.

Find out more about how you can short CRISPR Therapeutics stock.

CRISPR Therapeutics share dividends

We're not expecting CRISPR Therapeutics to pay a dividend over the next 12 months.

CRISPR Therapeutics share price volatility

Over the last 12 months, CRISPR Therapeutics's shares have ranged in value from as little as $32.3 up to $210.39. A popular way to gauge a stock's volatility is its "beta".

CRSP.US volatility(beta: 2.36)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CRISPR Therapeutics's is 2.3632. This would suggest that CRISPR Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

CRISPR Therapeutics overview

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site